REBECCA JONES: Open Payments
NPI 1063623015 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$756 in 34 payments from 12 companies in 2025. Trend: 2023 $692 · 2024 $903 · 2025 $756
Food & beverage: $756
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $148 |
| Neuronetics, Inc. | 1 | $97 |
| Otsuka America Pharmaceutical, Inc. | 3 | $88 |
| Vanda Pharmaceuticals Inc. | 2 | $67 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $27 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| Tris Pharma Inc | 1 | $25 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $23 |
Products named: VRAYLAR, CAPLYTA, REXULTI, NEUROSTAR TMS THERAPY SYSTEM, FANAPT, Auvelity, TRINTELLIX, INGREZZA.
Industry payments across AL — which companies pay providers there.
